OpenLB
Open Library of Bioscience

How can polymyxin B be dosed based on current pharmacokinetic knowledge?

Abstract

No abstract text available.

References

1. Wang X, Xiong W, Zhong M et al (2024) Pharmacokinetics of polymyxin B in different populations: a systematic review. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-024-03666-w [DOI: 10.1007/s00228-024-03666-w]
2. Wang P, Liu S, Sun T, Yang J (2024) Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis. Int J Antimicrob Agents 63:107099. https://doi.org/10.1016/j.ijantimicag.2024.107099 [DOI: 10.1016/j.ijantimicag.2024.107099]
3. Hanafin PO, Kwa A, Zavascki AP et al (2023) A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients. Clin Microbiol Infect 29:1174���1181. https://doi.org/10.1016/j.cmi.2023.05.018 [DOI: 10.1016/j.cmi.2023.05.018]
4. Liang D, Liang Z, Deng G et al (2023) Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients. Front Pharmacol 14:1122310. https://doi.org/10.3389/fphar.2023.1122310 [DOI: 10.3389/fphar.2023.1122310]
5. Li X, Cheng Y, Chen B et al (2023) Population pharmacokinetics of polymyxin B in patients with liver dysfunction. Br J Clin Pharmacol 89:3561���3572. https://doi.org/10.1111/bcp.15855 [DOI: 10.1111/bcp.15855]
6. Surovoy YA, Burkin MA, Galvidis IA et al (2023) Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis. Eur J Clin Pharmacol 79:79���87. https://doi.org/10.1007/s00228-022-03415-x [DOI: 10.1007/s00228-022-03415-x]
7. Yu Z, Liu X, Du X et al (2022) Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae. Front Pharmacol 13:97566. https://doi.org/10.3389/fphar.2022.975066 [DOI: 10.3389/fphar.2022.975066]
8. Ye Q, Wang Q, Chen W et al (2022) The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation. J Clin Pharm Ther 47:1608���1618. https://doi.org/10.1111/jcpt.13711 [DOI: 10.1111/jcpt.13711]
9. Wang P, Liu D, Sun T et al (2022) Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 60:106693. https://doi.org/10.1016/j.ijantimicag.2022.106693 [DOI: 10.1016/j.ijantimicag.2022.106693]
10. Wang P, Xing H, Zhang F et al (2022) Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration. Int J Antimicrob Agents 60:106599. https://doi.org/10.1016/j.ijantimicag.2022.106599 [DOI: 10.1016/j.ijantimicag.2022.106599]
11. Wang PL, Liu P, Zhang QW et al (2022) Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections. J Antimicrob Chemother 77:3000���3008. https://doi.org/10.1093/jac/dkac265 [DOI: 10.1093/jac/dkac265]
12. Cai XJ, Chen Y, Zhang XS et al (2022) Population pharmacokinetic analysis, renal safety, and dosing optimization of polymyxin B in lung transplant recipients with pneumonia: A prospective study. Front Pharmacol 13:1019411. https://doi.org/10.3389/fphar.2022.1019411 [DOI: 10.3389/fphar.2022.1019411]
13. Luo X, Zhang Y, Liang P et al (2022) Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with/without continuous renal replacement therapy. Eur J Pharm Sci 175:106214. https://doi.org/10.1016/j.ejps.2022.106214 [DOI: 10.1016/j.ejps.2022.106214]
14. Wang P, Zhang Q, Feng M et al (2021) Population pharmacokinetics of polymyxin B in obese patients for resistant gram-negative infections. Front Pharmacol 12:754844. https://doi.org/10.3389/fphar.2021.754844 [DOI: 10.3389/fphar.2021.754844]
15. Li Y, Deng Y, Zhu ZY et al (2021) Population pharmacokinetics of polymyxin B and dosage optimization in renal transplant patients. Front Pharmacol 12:727170. https://doi.org/10.3389/fphar.2021.727170 [DOI: 10.3389/fphar.2021.727170]
16. Yu XB, Jiao Z, Zhang CH et al (2021) Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions. Br J Clin Pharmacol 87:1869���1877. https://doi.org/10.1111/bcp.14576 [DOI: 10.1111/bcp.14576]
17. Wang P, Zhang Q, Zhu Z et al (2021) Comparing the population pharmacokinetics of and acute kidney injury due to polymyxin B in Chinese patients with or without renal insufficiency. Antimicrob Agents Chemother 65:e01900-e1920. https://doi.org/10.1128/AAC.01900-20 [DOI: 10.1128/AAC.01900-20]
18. Crass RL, Al NT, Wen B et al (2021) Pharmacokinetics of polymyxin B in hospitalized adults with cystic fibrosis. Antimicrob Agents Chemother 65:e00792-e821. https://doi.org/10.1128/AAC.00792-21 [DOI: 10.1128/AAC.00792-21]
19. Wang P, Zhang Q, Zhu Z et al (2020) Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant gram-negative bacterial infections. Front Pharmacol 11:829. https://doi.org/10.3389/fphar.2020.00829 [DOI: 10.3389/fphar.2020.00829]
20. Manchandani P, Thamlikitkul V, Dubrovskaya Y et al (2018) Population pharmacokinetics of polymyxin B. Clin Pharmacol Ther 104:534���538. https://doi.org/10.1002/cpt.981 [DOI: 10.1002/cpt.981]
21. Miglis C, Rhodes NJ, Avedissian SN et al (2018) Population pharmacokinetics of polymyxin B in acutely Ill adult patients. Antimicrob Agents Chemother 62:e01475-e1517. https://doi.org/10.1128/AAC.01475-17 [DOI: 10.1128/AAC.01475-17]
22. Avedissian SN, Miglis C, Kubin CJ et al (2018) Polymyxin B pharmacokinetics in adult cystic fibrosis patients. Pharmacotherapy 38:730���738. https://doi.org/10.1002/phar.2129 [DOI: 10.1002/phar.2129]
23. Sandri AM, Landersdorfer CB, Jacob J et al (2013) Population pharmacokinetics of intravenous polymyxin B in critically Ill patients: Implications for selection of dosage regimens. Clin Infect Dis 57:524���531. https://doi.org/10.1093/cid/cit334 [DOI: 10.1093/cid/cit334]
24. Zheng Y, Xu B, Chen S et al (2023) Population pharmacokinetic modeling using polymyxin B free plasma concentrations from published reports and evaluation of dosage regimens based on Monte Carlo simulation in critically ill patients. J Clin Pharmacol 63:1036���1044. https://doi.org/10.1002/jcph.2261 [DOI: 10.1002/jcph.2261]
25. Liu X, Huang C, Bergen PJ et al (2023) Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society. J Zhejiang Univ Sci B 24:130���142. https://doi.org/10.1631/jzus.B2200466 [DOI: 10.1631/jzus.B2200466]
26. Tsuji BT, Pogue JM, Zavascki AP et al (2019) International consensus guidelines for the optimal use of the polymyxins. Pharmacotherapy 39:10���39. https://doi.org/10.1002/phar.2209 [DOI: 10.1002/phar.2209]

MeSH Term

Chemicals